Price Alert

Royalty Pharma (RPRX)

NASDAQ: RPRX · Real-Time Price · USD

36.34

-0.16 (-0.44%)

At close: Aug 15, 2025, 3:59 PM

36.35

0.03%

After-hours: Aug 15, 2025, 04:10 PM EDT

-0.44% (1D)

Bid	35.85
Market Cap	15.71B
Revenue (ttm)	2.31B
Net Income (ttm)	1.02B
EPS (ttm)	2.29
PE Ratio (ttm)	15.87
Forward PE	7.45
Analyst	Strong Buy

Ask	36.8
Volume	1,708,107
Avg. Volume (20D)	4,258,177
Open	36.38
Previous Close	36.50
Day's Range	36.07 - 36.60
52-Week Range	24.05 - 38.00
Beta	0.54

About RPRX

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol RPRX

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for RPRX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Royalty Pharma has released their quartely earnings on Aug 6, 2025:

Revenue of $579M misses estimates by $111.73M, with 7.82% YoY growth.

EPS of 1.14 exceeds estimates by 0.09, with 18.75% YoY growth.

Next Earnings Release

Royalty Pharma is scheduled to release its earnings on Nov 5, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

7 months ago

+12.56%

Royalty Pharma shares are trading higher after the... Unlock content with Pro Subscription

News

6 days ago · seekingalpha.com

Royalty Pharma: Keep Delivering, Buy Confirmed

Robust quarterly performance with royalty receipts and adjusted EBITDA by +11% and +13%, respectively. New catalysts are emerging with recurrent billion‑dollar transactions and Chinese royalty opportu...

1 week ago · fool.com

Royalty Pharma (RPRX) Q2 Receipts Up 20%

1 week ago · seekingalpha.com

Royalty Pharma plc (RPRX) Q2 2025 Earnings Call Transcript

Royalty Pharma plc (NASDAQ:RPRX ) Q2 2025 Earnings Conference Call August 6, 2025 8:00 AM ET Company Participants George Grofik - Senior VP and Head of Investor Relations & Communications Marshall Jon...

1 week ago · zacks.com

Here's What Key Metrics Tell Us About Royalty Pharma (RPRX) Q2 Earnings

The headline numbers for Royalty Pharma (RPRX) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street es...

1 week ago · zacks.com

Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates

Royalty Pharma (RPRX) came out with quarterly earnings of $1.14 per share, beating the Zacks Consensus Estimate of $1.1 per share. This compares to earnings of $0.96 per share a year ago.

1 week ago · zacks.com

Countdown to Royalty Pharma (RPRX) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS

Evaluate the expected performance of Royalty Pharma (RPRX) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metr...

2 weeks ago · youtube.com

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...

2 weeks ago · youtube.com

President Trump demands drugmakers slash prices within 60 days

CNBC's Joe Kernen reports on the latest news.

2 weeks ago · zacks.com

Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy?

Royalty Pharma (RPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago · seekingalpha.com

Royalty Pharma: Attractive Acquisition With Upside Risk/Reward On Current Pipeline

Royalty Pharma is less exposed to MFN drug pricing risks, offering downside protection in a volatile policy environment. The Revolution Medicines royalty deal provides near-term upside and de-risks pi...

Load More News